Instituto Global para la Excelencia en el Cuidado de la Salud Keralty2026-07-082026-07-082022https://repositorio.unisanitas.edu.co/handle/123456789/1173COVID-19 antiviral treatments are still in the early stages of development, considering that the disease was first identified in late 2019. COVID-19 nirmatrelvir is recommended for use in patients older than 12 years and weighing more than 40 kilograms with risk factors for moderate COVID-19 and who already have a positive COVID-19 test. The risks of using nirmatrelvir appear to be lower than the potential benefits.textenDocumento